Michael Overdorf net worth and biography

Michael Overdorf Biography and Net Worth

EVP of Annexon

Michael Overdorf has served as our Executive Vice President and Chief Business Officer since July 2020. Prior to joining Annexon, from 2001 to 2020, Mr. Overdorf held various executive leadership roles at Eli Lilly and Company, most recently in Corporate Business Development and Corporate Strategy where he led teams focused on accessing innovative medicines and led the development and execution of the company’s global strategy. Mr. Overdorf also served as a Global Biologics Platform Team Leader, leading two Phase 3 clinical development teams working on biologic molecules targeting autoimmune diseases and as the Chief Operating Officer of the Bio-Medicines Business Unit of Lilly. Mr. Overdorf also held multiple commercial leadership roles at Lilly, including Chief Marketing Officer of the United Kingdom and General Manager of the Czech & Slovak Republics. Mr. Overdorf is an adjunct lecturer in Medicine in the Division of Clinical Pharmacology at the Indiana University School of Medicine. Mr. Overdorf received a BA in Economics from Wabash College and an MBA from Harvard Business School.

What is Michael Overdorf's net worth?: The estimated net worth of Michael Overdorf is at least $586.79 thousand as of July 14th, 2025. Overdorf owns 130,689 shares of Annexon stock worth more than $586,794 as of December 5th. This net worth evaluation does not reflect any other investments that Overdorf may own. Additionally, Overdorf receives a salary of $580,470.00 as EVP at Annexon. Learn More about Michael Overdorf's net worth.
How old is Michael Overdorf?: Overdorf is currently 53 years old. There are 5 older executives and no younger executives at Annexon. The oldest executive at Annexon is Dr. Ted Yednock Ph.D., Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board, who is 66 years old. Learn More on Michael Overdorf's age.
What is Michael Overdorf's salary?: As the EVP of Annexon, Inc., Overdorf earns $580,470.00 per year. There are 4 executives that earn more than Overdorf. The highest earning executive at Annexon is Mr. Douglas Love Esq., J.D., CEO, President & Director, who commands a salary of $980,120.00 per year. Learn More on Michael Overdorf's salary.
How do I contact Michael Overdorf?: The corporate mailing address for Overdorf and other Annexon executives is , , . Annexon can also be reached via phone at 650-822-5500 and via email at [email protected]. Learn More on Michael Overdorf's contact information.
Has Michael Overdorf been buying or selling shares of Annexon?: Michael Overdorf has not been actively trading shares of Annexon during the past quarter. Most recently, Michael Overdorf sold 853 shares of the business's stock in a transaction on Monday, July 14th. The shares were sold at an average price of $2.61, for a transaction totalling $2,226.33. Following the completion of the sale, the executive vice president now directly owns 130,689 shares of the company's stock, valued at $341,098.29. Learn More on Michael Overdorf's trading history.
Who are Annexon's active insiders?: Annexon's insider roster includes Dean Artis (EVP), William Carson (Director), Jamie Dananberg (Insider), Sanjay Keswani (EVP), Jennifer Lew (CFO), Douglas Love (CEO), Michael Overdorf (EVP), Muneer Satter (Director), and Ted Yednock (EVP). Learn More on Annexon's active insiders.
Are insiders buying or selling shares of Annexon?: During the last twelve months, Annexon insiders bought shares 10 times. They purchased a total of 1,876,188 shares worth more than $7,268,165.34. During the last twelve months, insiders at the sold shares 12 times. They sold a total of 32,352 shares worth more than $93,274.67. The most recent insider tranaction occured on December, 1st when Director Jung Choi bought 33,000 shares worth more than $138,270.00. Insiders at Annexon own 11.9% of the company. Learn More about insider trades at Annexon.
Information on this page was last updated on 12/1/2025.

Michael Overdorf Insider Trading History at Annexon

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/14/2025	Sell	853	$2.61	$2,226.33	130,689
7/14/2025	Sell	853	$2.61	$2,226.33	130,689
2/13/2025	Sell	1,425	$2.99	$4,260.75	93,197
7/15/2024	Sell	784	$6.02	$4,719.68	94,622
2/12/2024	Sell	1,349	$5.53	$7,459.97	48,592
2/13/2023	Sell	1,501	$6.30	$9,456.30	27,949

Michael Overdorf Buying and Selling Activity at Annexon

Annexon Company Overview

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Today's Range

Now: $4.49

$4.25

$4.55

50 Day Range

MA: $3.38

$2.68

$4.51

2 Week Range

Now: $4.49

$1.28

$5.66

Volume

2,488,278 shs

Average Volume

3,148,846 shs

Market Capitalization

$537.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2

Michael Overdorf Biography and Net Worth

What is Michael Overdorf's net worth?

How old is Michael Overdorf?

What is Michael Overdorf's salary?

How do I contact Michael Overdorf?

Has Michael Overdorf been buying or selling shares of Annexon?

Who are Annexon's active insiders?

Are insiders buying or selling shares of Annexon?